|

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

RECRUITINGN/ASponsored by Neolys
Actively Recruiting
PhaseN/A
SponsorNeolys
Started2023-12-02
Est. completion2027-08-30
Eligibility
Age3 Years – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06033183

Summary

Analysis of the individual radiosensitivity in pediatric oncology

Eligibility

Age: 3 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
* Children or adolescents \> 3 years old and \< 18 years old
* Patient with an indication for radiotherapy as part of the primary tumor local control strategy
* Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
* Patient affiliated with a social security scheme
* Patient and/or parents or holders of parental authority having dated and signed an informed consent

Exclusion criteria:

* Patients with contraindications to blood sampling
* Patients with contraindications to radiotherapy
* Palliative radiotherapy
* Patient with previous RT treatment in the same area (re-irradiation)
* Patient with an indication of hypofractionated RT
* Patient follow-up not possible
* Persons deprived of liberty or under guardianship (including curatorship)

Exclusion Criteria:

\-

Conditions4

CancerPediatric CancerRadiation ToxicityRadiosensitivity

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.